On an adjusted basis, the company reported a profit of $1.65 per share, compared with analysts' average estimate of $1.60, according to LSEG data.

Larger peers Abbott Laboratories and Boston Scientific had also topped quarterly profit estimates on easing staffing shortages and a surge in hospital admissions for elective procedures deferred during the pandemic.

However, Zimmer cut its full-year reported revenue forecast to a growth of 6% to 6.5% from 6.5% to 7.0% earlier, citing a stronger dollar.

Sales at the company's knees unit rose 7.5% to $706.3 million, compared to analysts' estimate of $702.9 million.

The Indiana-based company's third-quarter revenue rose 5% to $1.75 billion, in line with analysts' average estimates.

Zimmer had said earlier that it expects second- and third-quarter revenue to be a "little bit lighter" compared to the first quarter.

The hip and knee implant maker reiterated its full-year profit forecast of $7.47 to $7.57 per share.

(Reporting by Christy Santhosh in Bengaluru; Editing by Sriraj Kalluvila)